MCID: PMC5365720 DOI: 10.1128/AAC.02014-16
Although obesity is prevalent among children in the United States, pharmacokinetic (PK) data for obese children are limited. Clindamycin is a commonly used antibiotic that may require dose adjustment in obese children due to its lipophilic properties. We performed a clindamycin population PK analysis using data from three separate trials. A total of 420 samples from 220 children, 76 of whom had a body mass index greater than or equal to the 95th percentile for age, were included in the analysis. Compared to other metrics, total body weight (TBW) was the most robust measure of body size. The final model included TBW and a sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL (liters/hour) = 13.8 × (TBW/70)
Antimicrobial agents and chemotherapy
Adolescent; Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; Biological Availability; Body Mass Index; Body Weight; Child; Clindamycin; Drug Administration Schedule; Drug Dosage Calculations; Female; Humans; Injections, Intravenous; Male; Models, Statistical; Obesity; Orosomucoid; Serum Albumin
antibiotics; children; clindamycin; obesity; pharmacokinetics
Smith, Michael J.; Gonzalez, Daniel; Goldman, Jennifer L; Yogev, Ram; Sullivan, Janice E.; Reed, Michael D.; Anand, Ravinder; Martz, Karen; Berezny, Katherine; Benjamin, Daniel K.; Smith, P Brian; Cohen-Wolkowiez, Michael; and Watt, Kevin, "Pharmacokinetics of Clindamycin in Obese and Nonobese Children." (2017). Manuscripts, Articles, Book Chapters and Other Papers. 1104.